Chemical Property of Mycophenolate mofetil
Chemical Property:
- Vapor Pressure:7.51E-17mmHg at 25°C
- Melting Point:93-94oC
- Refractive Index:1.557
- Boiling Point:637.6oC at 760 mmHg
- Flash Point:339.4oC
- PSA：94.53000
- Density:1.222 g/cm3
- LogP:2.46190
- Solubility.:Practically insoluble in water, freely soluble in acetone, sparingly soluble in anhydrous ethanol.
- Purity/Quality:
-
99%, *data from raw suppliers
Mycophenolate Mofetil *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
-
Uses
It is mainly used for prevention the allograft rejection reaction upon organ transplant as mostly seen in renal transplant and also suitable in the heat, liver transplant especially for the refractory rejection reaction after the transplant. It can be combined together with cyclosporine and corticosteroids. It can also be applied to rheumatoid arthritis, systemic lupus erythematosus, primary glomerulonephritis, psoriasis and some other autoimmune diseases. Apply oral administration in kidney transplant; initial dose: 2~3mg/kg per day, maintenance dose: 1~2mg/ kg per day and take in 2 to 3 times. The dose can be adjusted according to specific condition. Rheumatoid arthritis: 300 mg daily. Inhibitor of nucleic acid synthesis; immunomodulator. Mycophenolate Mofetil is an intermediate in the synthesis of (4Z)-Mycophenolate Mofetil (M831455), a degradation product of Mycophenolate mofetil, an immunosuppressant.
-
Indications
Mycophenolate mofetil (CellCept), in conjunction with
cyclosporine and corticosteroids, has clinical applications
in the prevention of organ rejection in patients receiving
allogeneic renal and cardiac transplants. By effectively
inhibiting de novo purine synthesis, it can
impair the proliferation of both T and B lymphocytes.
Following oral administration, mycophenolate mofetil
is almost completely absorbed from the GI tract, metabolized
in the liver first to the active compound mycophenolic
acid, and then further metabolized to an inactive
glucuronide.
Early clinical trials indicate that mycophenolate
mofetil in conjunction with cyclosporine and corticosteroids
is a more effective regimen than azathioprine
in preventing the acute rejection of transplanted organs.
GI side effects are most common.
